GSK's asthma drug Nucala gets speedy review for rare blood disorder

GSK's asthma drug Nucala gets speedy review for rare blood disorder

Source: 
Endpoints
snippet: 

GlaxoSmithKline’s asthma drug Nucala may not be on the same tier as rival Regeneron’s Dupixent, but it has scored a speedy review for use in a rare blood disorder.